Evidence map›Paper›PMID 40613710›Full record

ArticleNucleic acids research2025

Structural basis of a dual-function type II-B CRISPR-Cas9.

Grace N Hibshman, David W Taylor

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Grace N HibshmanDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, United States.
David W TaylorDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, United States.ORCID 0000-0002-6198-1194

Funding

Imaging macromolecular machines in gene regulationR35GM138348 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI TAYLOR, DAVID W · 2020 to 2024
$1.9M
NIGMS NIH HHS R35 GM138348NIH HHS R35GM138348Welch Foundation F-1938
6 · The paper itself

Abstract

Cas9 from Streptococcus pyogenes (SpCas9) revolutionized genome editing by enabling programmable DNA cleavage guided by an RNA. However, SpCas9 tolerates mismatches in the DNA-RNA duplex, which can lead to deleterious off-target editing. Here, we reveal that Cas9 from Francisella novicida (FnCas9) possesses a unique structural feature-the REC3 clamp-that underlies its intrinsic high-fidelity DNA targeting. Through kinetic and structural analyses, we show that the REC3 clamp forms critical contacts with the PAM-distal region of the R-loop, thereby imposing a novel checkpoint during enzyme activation. Notably, F. novicida encodes a noncanonical small CRISPR-associated RNA (scaRNA) that enables FnCas9 to repress an endogenous bacterial lipoprotein gene, subverting host immune detection. Structures of FnCas9 with scaRNA illustrate how partial R-loop complementarity hinders REC3 clamp docking and prevents cleavage in favor of transcriptional repression. The REC3 clamp is conserved across type II-B CRISPR-Cas9 systems, pointing to a potential path for engineering precise genome editors or developing novel antibacterial strategies. These findings reveal the molecular basis of heightened specificity and virulence enabled by FnCas9, with broad implications for biotechnology and therapeutic development.

Indexed as

Bacterial ProteinsCRISPR-Associated Protein 9CRISPR-Cas SystemsFrancisellaDNADNA CleavageGene EditingRNA, Guide, CRISPR-Cas SystemsStreptococcus pyogenesBacterial ProteinsCRISPR-Associated Protein 9DNARNA, Guide, CRISPR-Cas Systems

Identifiers

PMID40613710
PMCPMC12231574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.